CytoDyn color logo - no R.png
CytoDyn to Present at Emerging Growth Conference on October 13 Followed by Live Q/A
October 07, 2021 14:27 ET | CytoDyn Inc.
VANCOUVER, Washington, Oct. 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
CytoDyn color logo - no R.png
CytoDyn Announces Study to Evaluate Potential Synergistic Effects of Leronlimab with Immune Checkpoint Blockade (ICB)
October 07, 2021 06:02 ET | CytoDyn Inc.
Clinical Trial Development Targeting Triple-Negative Breast Cancer (TNBC) to Evaluate Anti-Tumor Effects and Identify Immunological Biomarkers for Leronlimab in Combination with Immune Checkpoint...
CytoDyn color logo - no R.png
CytoDyn Names Chris Recknor, M.D. Senior Executive VP of Clinical Operations to Initiate Two New Clinical Trials for Stroke and Alzheimer’s, While Nitya Ray, Ph.D. is Named CytoDyn’s New COO to Lead CMC and Regulatory Operations Specifically the BLA for HIV
October 07, 2021 06:01 ET | CytoDyn Inc.
New hires in Bioanalytical Sciences, Biostatistics, Clinical Regulatory, and Clinical Project Management will join the team of Drs. Srinivasan, Recknor, Ray, and Kelly to lead all clinical trials with...
CytoDyn color logo - no R.png
CytoDyn Announces Legal Actions Against its Former CRO, Amarex Clinical Research
October 07, 2021 06:00 ET | CytoDyn Inc.
All clinical activities have been moved away from Amarex; a complete update on all activities will be provided to shareholders next week by Drs. Recknor, Kelly, Ray, and Pourhassan VANCOUVER,...
CytoDyn color logo - no R.png
CytoDyn to Present at Emerging Growth Conference on September 15 Follow by Live Q/A
September 13, 2021 06:00 ET | CytoDyn Inc.
VANCOUVER, Washington, Sept. 13, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
CytoDyn color logo - no R.png
CytoDyn Announces Treatment of the First Patient in its Pivotal Phase 3 COVID-19 Trial in Brazil for Patients with Severe Symptoms
September 09, 2021 20:30 ET | CytoDyn Inc.
An interim analysis will be conducted 28 days following enrollment of 245 patients (40% of targeted trial patients) VANCOUVER, Washington, Sept. 09, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:...
CytoDyn color logo - no R.png
CytoDyn to Hold Webcast on September 8 to Discuss Results from mTNBC Trials, HIV BLA Status, and Updates on COVID-19 and NASH Trials
September 02, 2021 18:40 ET | CytoDyn Inc.
VANCOUVER, Washington, Sept. 02, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
CytoDyn color logo - no R.png
CytoDyn Appoints Seenu Srinivasan, Ph.D. as Executive Director of CMC Regulatory Affairs
August 26, 2021 17:02 ET | CytoDyn Inc.
Dr. Srinivasan provides 30 years of broad regulatory and drug development experience including a career serving as Director of CMC Regulatory Affairs for Regeneron Pharmaceuticals, Inc. where he led...
CytoDyn color logo - no R.png
CytoDyn’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival
August 25, 2021 08:00 ET | CytoDyn Inc.
Decreases in Circulating Tumor Cells after leronlimab induction were seen in 73% of the patients and associated with increase in PFS and OS CytoDyn plans to update its Breakthrough Therapy...
CytoDyn color logo - no R.png
CytoDyn Receives FDA Guidance for its HIV BLA Dose Justification Report
August 13, 2021 06:00 ET | CytoDyn Inc.
Company Believes All Issues Are Addressable and it Will Be Able to Continue BLA Resubmission CMC and Non-Clinical Sections Will Be Fully Resubmitted as Early as September 2021 VANCOUVER,...